Replies to post #88232 on Biotech Values

[urche]

That would help explain the dismal performance of SBS.

If both the insulin and apo-A1 programs are hampered by serious limitations (one lacking a market and the other lacking a route to market), then that doesn't leave much value---but a mighty fine story!